An in vivo platform for translational drug development in pancreatic cancer

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4652-4661

  Rubio Viqueira, Belen ^a   Jimeno, Antonio ^a   Cusatis, George ^a   Zhang, Xianfeng ^a   Iacobuzio Donahue, Christine ^a   Karikari, Collins ^a   Shi, Chanjusn ^a   Danenberg, Kathleen ^b   Danenberg, Peter V ^d   Kuramochi, Hidekazu ^d   Tanaka, Koji ^d   Singh, Sharat ^c   Salimi Moosavi, Hossein ^c   Bouraoud, Nadia ^a   Amador, Maria L ^a   Altiok, Soner ^a   Kulesza, Piotr ^a   Yeo, Charles ^a   Messersmith, Wells ^a   Eshleman, James ^a   Hruban, Ralph H ^a   Maitra, Anirban ^a   Hidalgo, Manuel ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Response Genetics Inc   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CL 1040; ERLOTINIB; GEMCITABINE; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL HETEROGENEITY; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; EXPERIMENTAL MODEL; GENE EXPRESSION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; KINETICS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; SIROLIMUS; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748088524     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0113     Document Type: Article

References (45)

1. Yeo TP, Hruban RH, Leach SD, et al. Pancreatic cancer. Curr Probl Cancer 2002;26:176-275.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
4. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
5. Moore M, Goldstein D, Hamm J, Figer A, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Asco 2005.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-45.
9. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
10. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
11. Walter K, Eshleman J, Goggins M. Xenografting and harvesting human ductal pancreatic adenocarcinomas for DNA analysis. Methods Mol Med 2005;103:103-11.
12. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
13. Shi C, Eshleman SH, Jones D, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Methods 2004;1:141-7.
14. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54.
15. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
16. Hatzis P, Al-Madhoon AS, Jullig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998;273:30239-43.
17. Chan-Hui PY, Stephens K, Warnock RA, Singh S. Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 2004;111:162-74.
18. Kakimoto M, Uetake H, Osanai T, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test. Cancer Lett 2005;223:103-11.
19. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
20. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-21.
21. Schneider S, Uchida K, Brabender J, et al. Down-regulation of TS, DPD, ERCC1, GST-Pi EGFR, HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005;200:336-44.
22. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-25.
23. Lord RV, Park JM, Wickramasinghe K, et al. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246-53.
24. Salonga DS, Danenberg KD, Grem J, Park JM, Danenberg PV. Relative gene expression in normal and tumor tissue by quantitative RT-PCR. Methods Mol Biol 2002;191:83-98.
25. Lenz HJ, Danenberg KD, Leichman CG, et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998;4:1227-34.
26. Bocsi J, Zalatnai A. Establishment and long-term xenografting of human pancreatic carcinomas in immunosuppressed mice: changes and stability in morphology, DNA ploidy and proliferation activity. J Cancer Res Clin Oncol 1999;125:9-19.
27. Reyes G, Villanueva A, Garcia C, et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996;56:5713-9.
28. Sorio C, Bonora A, Orlandini S, et al. Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch 2001;438:154-8.
29. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-8.
30. Giovanella BC, Vardeman DM, Williams LJ, et al. Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer 1991;47:66-71.
31. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 2002;87:200-6.
32. Fichtner I, Slisow W, Gill J, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004;40:298-307.
33. Kroep JR, Loves WJ, van der Wilt CL, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002;1:371-6.
34. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-24.
35. Westra JL, Hollema H, Schaapveld M, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005;16:1646-53.
36. Inoue T Hibi K, Nakayama G, et al. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer. J Gastroenterol 2005;40:143-7.
37. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65-77.
38. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003;17:2998-3010.
39. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
40. Yeo CJ. The recent past and future of adjuvant therapy for pancreatic cancer. Ann Surg Oncol 2003;10:488-9.
41. Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 2004;5:525-31.
42. Baselga J, Arribas J. Treating cancer's kinase "addiction." Nat Med 2004;10:786-7.
43. Adjei AA, Hidalgo M. Treating cancer by blocking cell signals. J Clin Oncol 2005;23:5279-80.
44. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93.
45. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62.